Sector: Life Sciences

Latest content

Leadership profile: Henry Hadad

Featured in Special Report 2021 Q3: IP leadership - what it is and why it matters

09 September 2021

English Court of Appeal brings sufficiency test into line with EPO case law

A recent UK judgment is good news for owners of patents claiming large numbers of compounds

07 September 2021

Pfizer: light on patent filings and heavy on abandonments

An IP purge between 2011 and 2015 saw the lapse of many of the rights the pharma giant developed itself, as well as a number of those it had acquired

07 September 2021

Bolsonaro vetoes Brazil’s first-of-a-kind compulsory tech transfer law

The president’s rejection of forced know-how licensing will now be reviewed by the country’s Congress, but a new patent suspension regime is set to come into force

03 September 2021

CAFC overturns $1.2 billion damages in another Section 112 blow for biotech genus IP

Juno Therapeutics and its partner Sloan Kettering Memorial Cancer Center lose out after the Federal Circuit invalidates a key patent under written description rules

02 September 2021

PTAB proceedings are a vital tool in the biologics space, despite low usage rates

While generic enthusiasm for IPRs has waned, administrative challenges are of growing importance to biosimilar producers

31 August 2021

First FDA interchangeable approval is a potential gamechanger for biosimilar patent strategy

Move could change the shape of the healthcare market and herald a rewrite of the life sciences IP playbook

27 August 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market

26 August 2021

IAM parent company acquires market-leading US patent litigation data and analytics firm

Austin-based Docket Navigator - which also covers trademarks, antitrust and other legal practice areas - becomes a Law Business Research company

25 August 2021

AbbVie looks set to recreate Humira patent thicketing success following Imbruvica victory

District of Delaware decision clears the way for the company to generate billions of dollars in sales well into the next decade

24 August 2021

Get unlimited access to all IAM content